Pecan (Carya illinoinensis): A Comprehensive Reference
1. Identity and Botanical Classification
1.1 Botanical and Chemical Names
Pecan is a deciduous monoecious nut tree belonging to the genus Carya of the family Juglandaceae. Its accepted binomial name is Carya illinoinensis (Wangenh.) K. Koch. Carya illinoinensis (pecan nut) is the most widely cultivated economical edible nut crop. Although commonly called a "nut," the botanical classification of pecan is a drupe, which is a type of fruit with a central stone. Pecans belong to the same family as walnuts.
1.2 Etymology and Common Names
The name "pecan" is a Native American word of Algonquin origin that was used to describe "all nuts requiring a stone to crack." The word entered English through early colonial contact. In Spanish-speaking regions, the nut is often called nuez encarcelada or nuez de la Tierra; in French, noix de pacane. Today, hundreds of pecan varieties are still known by their given Native American names like Cheyenne, Sioux, Choctaw, Kiowa, and Creek.
1.3 Natural Source and Geography
Originating in central and eastern North America and the river valleys of Mexico, pecans were widely used by pre-colonial residents. Pecans are the only native major tree nut in North America. Dating back to the 1500s, these nuts have been an important food source for Indigenous peoples for thousands of years. The pecan tree is native to North America; however, it is also cultivated in other countries, such as Australia, Brazil, China, Israel, Peru, Argentina, and South Africa. Mexico accounts for 44% of global pecan production, surpassing the USA at 40% (kernel basis, metric tons, 2022/2023). The other pecan-producing countries include South Africa, Australia, Brazil, Israel, and Peru.
1.4 Common Forms and Preparations
Pecans are available and consumed in a wide variety of forms. Raw, unshelled, and shelled whole pecans are the most common commercial presentations. Processed forms include:
- Raw shelled halves or pieces
- Dry-roasted and oil-roasted (salted and unsalted)
- Candied or sweetened pecans
- Pecan meal and flour (ground kernels)
- Pecan oil, extracted from the kernels
- Pecan shell extracts (studied for polyphenol content)
Clinical studies have utilized 68 g portions of raw, unroasted pecans, with participants instructed to eat them in raw form but permitted to add them to other foods. Pecan nutshells (PNS) are particularly rich in polyphenols, with phenolic and flavonoid concentrations reported to be 5–20 times higher than those in the edible kernels, making the shell a subject of growing research interest as a bioactive by-product.
2. Traditional and Historical Use
2.1 Indigenous North American Traditions
As North America's only major native nut tree, Native Americans were the first to cultivate and use wild pecans, becoming a favored resource due to the nut's accessibility by waterway, ease of shelling over other North American nut species, and their great taste. Pecan fossils have been discovered in the remains of Native American settlements. The tradition of collecting, cracking, and eating pecans, which was started by Native Americans, has been passed down for generations.
Native pecan nuts were used in a variety of ways, including being roasted, boiled, or ground into flour. With a fall harvest and nutrient-packed fruit, pecans were a necessary staple for tribes during the winter months. Pecans were a staple in the Native American diet and were considered a major food source in the fall months. They also learned how to use the pecans to make nut milk known as powcohicora.
Fermented nuts were used in traditional Indigenous ceremonies. For example, fermented nuts were used by the Algonquin to make a drink known as "powcohiccora" that was consumed in sacred ritual, as well as during battles to enhance the bravery of fighters.
2.2 Medicinal Uses by Native Tribes
Extracts from pulverized pecan tree parts such as leaves and bark served medicinal purposes, including as antibacterial and antifungal agents, to treat ailments such as ringworm and nausea. The Comanche tribe ground pecan leaves into a poultice to treat ringworm. The Plains Apaches used the wood for handles on tools, while Kiowa tribes boiled pecan bark and gave the extract to sufferers of tuberculosis to "build up the lungs." The Lumbee used bark tea to treat upset stomach. The leaves of the tree are used as tea for the treatment of digestive and inflammatory processes and skin problems, while the infusion of its rinds is used for chronic diarrhea or as a tonic in anemia.
2.3 Post-Colonial History and Cultivation
After centuries foraging wild pecans, Native Americans began planting pecan trees and trading their harvest to European explorers, who quickly became enamored and helped spread the lore—and seed—of this local delicacy. United States Presidents George Washington and Thomas Jefferson were known to be early promoters of pecans. After a trip south, Thomas Jefferson returned to Virginia where he shared his possession of pecan nuts and seedlings with George Washington. Both men planted and grew the trees on their personal property. An African-American enslaved gardener from Louisiana named Antoine successfully recreated a grafting technique. The Best Pecan Exhibited award at the Philadelphia Centennial Exposition in 1876 went to Antoine, and his seeds were the first official planting of improved pecans.
3. Nutritional Composition
3.1 Macronutrients
According to the USDA National Nutrient Database, pecans provide per 100 g: energy 691 kcal, carbohydrates 13.86 g, protein 9.17 g, total fat 71.9 g, cholesterol 0 mg, and dietary fiber 9.6 g. Of the total fats, 6.18 g is saturated, 40.8 g is monounsaturated, and 21.61 g is polyunsaturated. In percentage terms, the fatty acid content consists of approximately 9% saturated, 59% monounsaturated, and 32% polyunsaturated fats. Pecans have no trans fats and, like all plant-based foods, naturally contain no cholesterol.
3.2 Key Fatty Acids
The main fatty acids found in the lipid fraction of pecan kernels were oleic (over 60%), linoleic, palmitic, stearic, and linolenic. A serving of pecans (30 g) provides about 25% more oleic acid than a serving of olive oil (one tablespoon). The lipid fraction of pecans is predominantly composed of monounsaturated and polyunsaturated fatty acids, particularly oleic and linoleic acids, which have been associated with anti-inflammatory effects and cardiovascular protection.
3.3 Vitamins and Minerals
Pecan kernels are a good source of vitamins A and E, the B vitamins, folic acid, calcium, magnesium, potassium, and zinc. They have a high amount of copper (1.2 mg per 100 g), magnesium (121 mg per 100 g), phosphorus (277 mg per 100 g), and zinc (4.53 mg per 100 g). Pecans contain 691 calories per 100 g, 9.17 g protein, 24.44 mg vitamin E (163% DV), 2.53 mg iron (32% DV), and 4.5 mg manganese (196% DV). A pecan-rich diet significantly increases participants' levels of dietary fiber, thiamin, magnesium, copper, and manganese.
4. Key Bioactive Constituents and Mechanisms of Action
4.1 Polyphenols
Pecans are known not only for their rich content of unsaturated fats but also for a diverse profile of phytochemical components. Among these are (poly)phenols such as ellagitannins, flavan-3-ols (e.g., catechins and epicatechins), and proanthocyanidins. Other phytochemicals include carotenoids, tocopherols, and phytosterols. Phenolic compounds constitute a major fraction of the antioxidant capacity in pecan kernels, with ellagic acid, gallic acid, catechin, and epicatechin identified as predominant phenolics. These compounds are known for their ability to scavenge free radicals, chelate metal ions, and modulate various cellular pathways involved in oxidative stress and inflammation.
Within polyphenols, several types have been described in pecan, such as flavanols, anthocyanidins, proanthocyanidins, phenolic acids, and ellagic acid. Pecan has been characterized as having a high concentration of flavonoids (34 mg/100 g of seed) and also containing epigallocatechin-3-gallate (EGCG), a powerful antioxidant agent. The (poly)phenol content and antioxidant capacity of pecans have been extensively studied across cultivars and growing regions. These typically include measurements of total phenolics, anthocyanins, flavonoids, proanthocyanidins, carotenoids, flavanols, and ortho-diphenols. Antioxidant activity is commonly assessed by assays such as ORAC, DPPH, FRAP, and ABTS.
Pecan extracts show high contents of total phenolics, condensed tannins, and high antioxidant activity. Concentrations of proanthocyanidins are 9-fold higher in hydroalcoholic extracts. Catechins have been identified as the major phenolic compounds in pecan nut shell samples.
4.2 Tocopherols (Vitamin E)
Pecan kernels contain significant amounts of tocopherols, particularly gamma-tocopherol, which contribute to their antioxidant defense mechanisms. The content of γ-tocopherol among cultivars ranged from 95.97 to 139.50 mg γ-tocopherol/g of kernel, and was predominant compared to β-tocopherol. These results are important since tocopherols are the main components of the vitamin E complex. Some studies report that γ-tocopherol is more potent as an antioxidant, anti-inflammatory, and cardioprotective agent than its homolog α-tocopherol.
Gamma-tocopherol (γ-tocopherol), a major isoform of vitamin E, exhibits potent antioxidant, anti-inflammatory, and anticancer properties. Unlike other tocopherol isoforms, γ-tocopherol effectively neutralizes reactive oxygen species (ROS) and reactive nitrogen species (RNS), providing robust cellular protection against oxidative damage and lipid peroxidation. Its anti-inflammatory effects are mediated through the modulation of pathways involving cyclooxygenase-2 (COX-2) and tumor necrosis factor-alpha (TNF-α), reducing chronic inflammation. Additionally, tocopherols and carotenoids provide lipid-phase protection by interrupting chain-propagation steps of lipid peroxidation.
4.3 Phytosterols
Researchers at the University of Georgia have determined that plant sterols are found naturally in pecans in concentrated amounts. Ninety percent of those pecan sterols are in the form of beta-sitosterol, which has been cited as a food component that competes with the absorption of cholesterol in the body and thus has the ability to lower blood cholesterol levels. Additional minor constituents in pecan kernels include phytosterols, which may contribute to cholesterol-lowering effects.
4.4 Fatty Acids and Synergistic Mechanisms
The LDL cholesterol-lowering response shown in pecan studies is greater than expected based on equations derived from dietary fatty acid profiles, and may not be solely due to the fatty acid composition of nuts. Other bioactive compounds present in nuts, including micronutrients, fiber, and phytochemicals, may also contribute to their cardio-protective effect by reducing inflammation, improving vascular reactivity as well as fasting glucose and insulin sensitivity, and by lowering oxidative stress status.
The complex phytochemical matrix of pecan kernels raises important considerations regarding synergistic interactions among different compound classes. Emerging evidence suggests that the biological activities observed in whole pecan kernel extracts may exceed the sum of individual compound activities, indicating potential synergistic or additive effects.
4.5 Carotenoids
The concentration and composition of carotenoids in pecan kernels vary during maturation, with dynamic changes observed as kernels transition from development to full ripeness. The bioavailability of carotenoids from pecan kernels may be influenced by the lipid matrix, as these fat-soluble compounds require adequate dietary fat for optimal absorption.
4.6 Cultivar and Processing Variation
Research summarizes variations in the phenolic composition of pecans from various parts of the world based on cultivar, maturity stage, postharvest storage, and processing. This variability means that the precise phytochemical content can differ substantially between commercial pecan products. The total extractable phenolic content, condensed tannin content, tocopherols, and antioxidant activity (ORAC) are significantly affected by the pecan cultivar.
5. Scientific Evidence by Health Area
5.1 Cardiovascular Health and Lipid Profiles
Evidence strength: Moderate to Strong for lipid outcomes; Weaker for vascular function.
The U.S. Food and Drug Administration (FDA) issued a qualified health claim stating that consuming 1.5 ounces of most nuts per day, including pecans, may reduce the risk of heart disease. However, pecans have a unique nutritional profile, rich in polyphenols, tocopherols, and plant sterols, which may offer added or synergistic health benefits beyond their fat content.
A review published in Nutrients evaluated 52 studies published between 2000 and 2025, including human clinical studies examining the physiological effects of pecan consumption across a range of cardiometabolic and other health-related outcomes. Two decades of research consistently show that pecans improve heart health by lowering "bad" LDL cholesterol, triglycerides, and total cholesterol.
A key randomized controlled trial (RCT) published in The Journal of Nutrition by University of Georgia researchers found that participants at risk for cardiovascular disease who ate pecans during an eight-week intervention showed significant improvements in total cholesterol, triglycerides, and LDL cholesterol. The dose of pecans in this study contained 24.9 g MUFA and 13.6 g PUFA, and this fatty acid profile was reflected in the nutrient analysis from the food diaries.
A more recent RCT published in the American Journal of Clinical Nutrition (2025) reported that intake of pecans in place of usual snacks decreased total cholesterol by 8.1 mg/dL (~3.6%), non-HDL cholesterol by 9.5 mg/dL (~5.8%), LDL cholesterol by 7.2 mg/dL (~6.0%), and triglycerides by 16.4 mg/dL (~4.2%) from baseline. These effects are considered clinically meaningful, with prior evidence suggesting that the LDL cholesterol reduction observed would be expected to lower the relative risk of a vascular event by 4.3%.
An earlier trial from Loma Linda University found that a "pecan" diet (which consisted of replacing 20% of the calories from the American Heart Association's Step I diet foods with pecans) lowered total cholesterol by 11.5%, while the Step I diet lowered total cholesterol by 5.2%. In addition, the pecan diet increased HDL "good" cholesterol whereas the Step I diet decreased HDL unfavorably. Triglycerides were also significantly lower with the pecan diet.
Multiple randomized controlled trials and meta-analyses have found that including pecans or other nuts in the diet can significantly reduce total cholesterol and LDL cholesterol, and may improve other cardiometabolic markers. Pecans exhibit a high level of polyphenols and other bioactive compounds that could support antioxidant activity and help reduce lipid oxidation, a process linked to oxidative stress.
Inconsistent effects are observed on vascular function, glycemia, and inflammation in the clinical literature, indicating that lipid improvements are the most robustly demonstrated cardiovascular effect.
Consuming ≥20% of daily energy from pecans has been shown to improve blood lipids and reduce dyslipidemia, but this exceeds dietary recommendations. The benefits of lower doses remain less clear.
5.2 Glycemic Control and Metabolic Health
Evidence strength: Preliminary; inconsistent results across trials.
Data from human clinical trials suggest that replacing foods/snacks with pecans improves overall diet quality and lipid profiles; however, inconsistent effects are observed on vascular function, glycemia, and inflammation. Epidemiological studies have shown that regular pecan consumption (approximately 42–68 g/day) is associated with improved lipid profiles, reduced LDL oxidation, enhanced endothelial function, and better glycemic control, though the glycemic evidence from clinical trials is less uniform.
Pecan has been characterized as having a high concentration of flavonoids and also containing epigallocatechin-3-gallate (EGCG), a powerful antioxidant agent that has been shown to present favorable health effects on obesity, cardiovascular, neurological diseases, and cancer. These compounds are readily bioavailable, and combined with the low carbohydrate content (10–15%), this suggests pecans may be a suitable dietary food for people with diabetes. This inference, however, comes from compositional analysis rather than dedicated glycemia RCTs in diabetic populations.
5.3 Body Weight and Satiety
Evidence strength: Moderate for weight neutrality; Promising but preliminary for satiety hormone effects.
Body weight changes after pecan intake are reported as neutral, with promising results on satiety peptides and appetite regulation. Regular consumption promotes feelings of fullness and healthy blood sugar control without causing irregular weight gain.
A 4-week randomised controlled trial examined the impact of a pecan-enriched diet (68 g pecans/day) on appetite in older adults (50–75 years) and found enhanced satiety hormone secretion and dampened appetite intensity. Specifically, there was an increase in fasting and postprandial peptide YY for the pecan group compared with control, though cholecystokinin and ghrelin did not differ. Body weight and body fat remained stable over the 4-week study period in both groups, suggesting pecans may be beneficial to appetite control and weight maintenance.
The differential effects of pecans versus other popular snack foods on appetite and blood markers of metabolism and satiety have not been well studied. One trial investigated the effects of a single mid-morning snack of pecans or tortilla chips on subjective appetite, food intake, blood measures of hormones and metabolites, and resting energy expenditure in twenty participants with overweight and obesity enrolled in a within-participants, randomized crossover trial.
The larger peptide YY (PYY) response and greater suppression of ghrelin observed after pecan meals align with previous reports of chronic pecan consumption. Both 4 and 8 weeks of daily pecan consumption have been shown to result in greater PYY responses in older adults and adults at risk for cardiovascular disease. Furthermore, 8 weeks of pecan consumption also led to greater suppression of ghrelin in those at-risk adults.
Previous research involving 8–19 weeks of peanut or pecan consumption resulted in a 5–11% increase in resting metabolic rate. Tree nuts are rich in protein, fibre and energy, which may prevent further food intake by inducing satiety.
5.4 Antioxidant Activity and Inflammation
Evidence strength: Mechanistically well-supported (in vitro and ex vivo); clinical trial evidence in humans is limited.
Pecan nutshells are particularly rich in polyphenols (gallic acid, ellagic acid, vanillic acid, catechins). Their antioxidant actions involve free radical scavenging, metal chelation, enhancement of enzymatic defenses, and modulation of redox signalling. In vitro studies demonstrate that kernel extracts possess substantial antioxidant capacity and exert antiproliferative and cytotoxic effects against various human cancer cell lines, including colon cancer cells, with evidence of apoptosis induction. These findings are from cell-based models and have not been confirmed in human clinical trials.
The anti-inflammatory effects of gamma-tocopherol are mediated through the modulation of pathways involving cyclooxygenase-2 (COX-2) and tumor necrosis factor-alpha (TNF-α), reducing chronic inflammation and its associated risks. Preclinical findings suggest protective roles in cardiovascular disease, diabetes, neurodegeneration, and cancer, mediated through reduced lipid peroxidation, improved glucose metabolism, neuroprotection, and anticarcinogenic activity. These preclinical results require confirmation in large, well-controlled human trials.
5.5 Cognitive and Neurological Health
Evidence strength: Very preliminary; no dedicated human RCTs on pecans and cognition identified.
Cognition and gut health are emerging areas of research with very limited data from both human and preclinical models, warranting further investigation. Emerging clinical evidence suggests that nut consumption, including pecans, may have neuroprotective benefits. Higher tree nut intake has been associated with better cognitive function in older adults, particularly in domains such as memory and executive function. These effects are likely mediated by pecans' antioxidant and anti-inflammatory properties. Rich in vitamin E, polyphenols, and ellagic acid, pecans counteract oxidative stress and inflammation, both of which are implicated in age-related cognitive decline. Although specific randomized controlled trials on pecans and cognitive outcomes are lacking, the broader tree nut literature provides some indirect support.
A 4-week placebo-controlled, randomized crossover trial on mixed tree nuts (30 g/day, not pecans alone) found that there was a positive effect of nuts on cognition following only 4 weeks of consumption in a healthy nonelderly sample, as well as upregulation of a microbial taxa associated with gut health. The effects appear to be independent of one another, but further exploration is required in those experiencing cognitive decline and/or gut dysbiosis. This study used a mixed nut product and its findings cannot be attributed solely to pecans.
5.6 Gut Microbiome
Evidence strength: Very preliminary; human-specific pecan data lacking.
Gut health is an emerging area of research with very limited data from both human and preclinical models, warranting further investigation. The dietary fiber (9.6 g per 100 g) and polyphenol content of pecans provide theoretical substrates for gut microbiota modulation. The fiber fraction includes compounds that may serve as prebiotics, potentially supporting beneficial microbial taxa. Dedicated human clinical trials examining pecan consumption and gut microbiome composition were not identified in the current literature.
5.7 Diet Quality
Researchers found that people who include pecans in their diets score higher on the Healthy Eating Index, which reflects overall better diet quality, especially when the nuts replace typical snack choices. Overall, the current literature supports the cardiometabolic benefits of pecans within healthy dietary patterns.
6. Body Systems Associated with Pecan
- Cardiovascular system: Lipid modulation (LDL, total cholesterol, triglycerides), endothelial function, and oxidized LDL reduction.
- Metabolic system: Glycemic modulation, insulin sensitivity, dyslipidemia management.
- Gastrointestinal system: Dietary fiber contributing to gut motility; emerging microbiome interest.
- Central nervous system / Brain: Neuroprotective potential via antioxidant and anti-inflammatory pathways; research in early stages.
- Endocrine system: Satiety hormone regulation (peptide YY, ghrelin).
- Musculoskeletal system: Mineral provision (magnesium, manganese, zinc, copper) supporting bone and muscle metabolism.
- Immune/inflammatory system: Polyphenol and gamma-tocopherol-mediated modulation of oxidative stress and inflammatory signalling (primarily in vitro evidence).
7. Dosage Forms and Dosages Reported in Studies
The following dosages reflect amounts used in peer-reviewed clinical trials and reviews; they are not prescriptive recommendations.
- FDA qualified health claim basis: The FDA issued a qualified health claim stating that consuming 1.5 ounces (approximately 42 g) of most nuts per day, including pecans, may reduce the risk of heart disease.
- Loma Linda University RCT (2001): An eight-week study at Loma Linda University used a "pecan" diet comprising 20% of total caloric intake replaced by pecans, resulting in significant lipid improvements.
- University of Georgia RCT (2021): The dose of pecans in this study contained 24.9 g MUFA and 13.6 g PUFA, supplied as whole pecans incorporated into the diet over eight weeks in adults at CVD risk.
- Satiety/appetite RCT (2023): A 4-week randomised controlled trial used 68 g pecans per day in older adults (50–75 years).
- American Journal of Clinical Nutrition RCT (2025): Pecans were consumed as a snack replacement in adults at increased cardiometabolic risk, with decreases in total cholesterol (~3.6%), non-HDL cholesterol (~5.8%), LDL cholesterol (~6.0%), and triglycerides (~4.2%) from baseline observed.
- Dose-response study: Consuming ≥20% of daily energy from pecans was shown to improve blood lipids and reduce dyslipidemia.
- Epidemiological association range: Regular pecan consumption of approximately 42–68 g/day is associated with improved lipid profiles, reduced LDL oxidation, enhanced endothelial function, and better glycemic control.
Pecans are consumed in their whole, raw or lightly processed form in these studies, not as isolated extracts or supplements. No standardized supplement dosage has been established in pharmacopeial monographs.
8. Safety Considerations and Interactions
8.1 Allergenicity
Peanuts and tree nuts (including pecan) are among the most frequent elicitors of food allergic reactions. While most patients with cow's milk and hens' egg allergy gain oral tolerance within the first years of life, peanut and tree nut allergy usually persist into adulthood. Only about 20% of peanut and about 10% of tree nut-allergic patients develop oral tolerance later in life. Peanuts and tree nuts can lead to severe, life-threatening reactions in patients and are the major elicitors of food-induced anaphylaxis in children and adults.
The prevalence of pecan nut allergy is increasing with its documentation in the United States, Canada, Australia, Europe, and Israel.
8.2 Cross-Reactivity with Walnut
Pecan and walnut allergy are found to be strongly correlated since the allergens from both have high sequence identity. A high prevalence of co-allergy between walnuts and pecan nuts has been reported. There is considerable clinical cross-reactivity between cashew and pistachio, and between walnut and pecan. OIT (oral immunotherapy) to walnut will offer protection to pecan. A prospective cohort study conducted on 83 tree nut-allergic patients found 57 patients sensitized to pecan, with clinical allergy to pecan nut reported to be 59.6%.
High coincidence of cashew and pistachio nut allergy and of walnut, pecan, and hazelnut allergy in the same individuals has been documented.
8.3 Energy Density and Weight Management Considerations
Pecans are incredibly calorie-dense, providing 691 calories per 100 g. A meta-analysis of 55 clinical trials showed that nut intake does not increase weight, BMI, or waist circumference regardless of the substitution instructions provided. However, with large doses of pecans, additional education about overall energy intake may be needed to ensure energy balance.
8.4 Sodium Content of Processed Pecans
Raw or unsalted roasted pecans have no sodium. However, dry-roasted or oil-roasted pecans with added salt are very high in sodium, providing 383 mg per 100 g serving. This is a relevant consideration for individuals managing blood pressure or sodium-restricted diets.
8.5 Oxalate Content
Pecans, like other tree nuts, contain oxalates. While exact values vary by preparation, individuals with a history of calcium oxalate kidney stones are generally advised to moderate intake of high-oxalate foods, including tree nuts. This is based on general nut-class guidance and is not specific to a pecan-only clinical study in the identified literature.
8.6 Aflatoxin Risk (Storage-Dependent)
Tree nuts can be subject to aflatoxin contamination under poor storage conditions. The USDA and FDA regulate allowable aflatoxin levels in commercial nut products. Proper drying, storage, and commercial processing procedures are critical to minimizing this risk.
8.7 Drug and Nutrient Interactions
No specific pharmacokinetic drug–pecan interaction studies were identified in the peer-reviewed literature. The high content of vitamin K in pecan leaves (used in traditional teas, not the kernel itself) and the fat-soluble bioactive content (tocopherols, carotenoids) of the kernel are theoretically relevant for individuals taking anticoagulants or fat-soluble vitamin supplements, but clinical interaction studies specific to pecan are lacking. High doses of gamma-tocopherol necessitate careful evaluation to minimize adverse effects.
8.8 Overall Safety Profile
In clinical trials at doses of 42–68 g/day over periods of 4–8 weeks, pecan consumption has been well-tolerated in healthy adults and those at cardiometabolic risk, with no serious adverse events reported in the identified literature. The current literature supports the cardiometabolic benefits of pecans within healthy dietary patterns. Although less studied than almonds or walnuts, emerging evidence suggests that pecan consumption offers significant health benefits.
References
Go back